Related Experiment Video
Updated: Jul 20, 2025

10:43
Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding
Published on: June 27, 2014
19.9K
A 3D-Printable, Low-Cost Obturator for Less Invasive Gynecologic Brachytherapy.
Sanika Rane1, Alexander Hanania1, Elisa Arango1
1Radiation Oncology, Baylor College of Medicine, Houston, USA.
Cureus
|August 1, 2023
Summary
A novel applicator for interstitial brachytherapy (ISBT) was designed to improve gynecologic cancer treatment, especially in low-resource areas. This cost-effective device reduces patient morbidity by eliminating transcutaneous needle insertions, minimizing injury risks.
Area of Science:
- Medical Devices
- Radiation Oncology
- Gynecologic Oncology
Background:
- Interstitial brachytherapy (ISBT) is crucial for treating gynecologic cancers.
- Current ISBT methods can lead to significant patient morbidity, including vaginal laceration and organ injury.
- Access to advanced radiation treatment is limited in low-resource settings.
Purpose of the Study:
- To design, develop, and evaluate a cost-effective applicator for ISBT.
- To minimize patient morbidity associated with gynecologic cancer radiation therapy.
- To facilitate access to curative radiation treatment in low-resource settings.
Main Methods:
- Computer-aided design (CAD) and 3D printing were used to create a prototype applicator.
- The applicator features 44 slotted channels for guided needle insertion, avoiding transcutaneous techniques.
- Preclinical testing involved usability, needle stability, and arrangement assessments using a gelatin phantom.
Main Results:
- A promising prototype was successfully developed, addressing limitations of traditional perineum-based templates.
- The applicator design aims to cover bulky tumors, reduce tissue/organ injury, and enable treatment for women post-hysterectomy.
- Preclinical tests confirmed the applicator's efficacy in meeting its design objectives.
Conclusions:
- The developed applicator shows potential for facilitating ISBT with reduced morbidity, particularly in underserved regions.
- This innovation may improve current methods for treating advanced gynecologic cancers.
- Further clinical validation is required, but the applicator demonstrates significant promise for improving patient outcomes.

